Modern pharmaceutical treatment of pulmonary arterial hypertension

被引：0

作者：

Batyraliev, T. A. ^{[1
]}

Ekinsi, E. ^{[1
]}

Niyazova-Karben, Z. A. ^{[1
]}

Preobrazhensky, D. V. ^{[2
]}

Pataraya, S. A. ^{[2
]}

机构：

[1] Sani Konukogly Med Ctr, Gaziantep, Turkey

[2] RF President Adm, Educ & Res Med Ctr, Moscow, Russia

来源：

CARDIOVASCULAR THERAPY AND PREVENTION | 2008年 / 7卷 / 08期

关键词：

Calcium antagonists; prostanoids; epoprostenol; trepostinil; iloprost; bosentan; sildenafil;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The review is devoted to modern pharmaceutical treatment of pulmonary arterial hypertension (PAH). In 1970-80s, it was based on high-dose calcium antagonists, CA (e.g., nifiedipine 240 mg/d), which were effective only in some patients with primary (idiopathic) PAH. CA were combined with digoxin, indirect anticoagulants and oxygen. In 1990s, PAH therapy included prostanoids, endothelin receptor (ER) blockers and phosphodiesterase (PDE) inhibitors, which are more selective pulmonary vasodilatators than CA, and therefore are safer for long-term treatment. Prospective studies have demonstrated that continuous intravenous infusion of epoprostenol and ET receptor blocker bosentan treatment improve survival of PAH patients receiving traditional therapy. Clinical effectiveness of epoprostenol is similar to that of subcutaneously administered trepostinil, and bosentan is similar to PDE inhibitor Type 5 sildenafil. Bosentan increases the effectiveness of intravenous epoprostenol and inhaled trepostinil.

引用

页码：94 / 104

页数：11

共 47 条

[1] Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension [J].

Badesch, DB ;

Bodin, F ;

Channick, RN ;

Frost, A ;

Rainisio, M ;

Robbins, IM ;

Roux, S ;

Rubin, LJ ;

Simonneau, G ;

Sitbon, O ;

Tapson, VF .

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (04) :227-246

[2] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial [J].

Badesch, DB ;

Tapson, VF ;

McGoon, MD ;

Brundage, BH ;

Rubin, LJ ;

Wigley, FM ;

Rich, S ;

Barst, RJ ;

Barrett, PS ;

Kral, KM ;

Jöbsis, MM ;

Loyd, JE ;

Murali, S ;

Frost, A ;

Girgis, R ;

Bourge, RC ;

Ralph, DD ;

Elliott, CG ;

Hill, NS ;

Langleben, D ;

Schilz, RJ ;

McLaughlin, VV ;

Robbins, IM ;

Groves, BM ;

Shapiro, S ;

Medsger, TA ;

Gaine, SP ;

Horn, E ;

Decker, JC ;

Knobil, K .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) :425-+

[3] Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].

Badesch, DB ;

Abman, SH ;

Ahearn, GS ;

Barst, RJ ;

McCrory, DC ;

Simonneau, G ;

McLaughlin, VV .

CHEST, 2004, 126 (01) :35S-62S

[4] Diagnosis and differential assessment of pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

Torbicki, A ;

Sitbon, O ;

Krowka, MJ ;

Olschewski, H ;

Gaine, S .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :40S-47S

[5] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[6] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[7] Beraprost therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

McGoon, M ;

McLaughlin, V ;

Tapson, V ;

Oudiz, R ;

Shapiro, S ;

Robbins, IM ;

Channick, R ;

Badesch, D ;

Rayburn, BK ;

Flinchbaugh, R ;

Sigman, J ;

Arneson, C ;

Jeffs, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125

[8] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].

Barst, Robyn J. ;

Langleben, David ;

Badesch, David ;

Frost, Adaani ;

Lawrence, E. Clinton ;

Shapiro, Shelley ;

Naeije, Robert ;

Galie, Nazzareno .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056

[9] Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension [J].

Channick, Richard N. ;

Olschewski, Horst ;

Seeger, Werner ;

Staub, Ted ;

Voswinckel, Robert ;

Rubin, Lewis J. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1433-1437

[10] Endothelin receptor antagonists in pulmonary arterial hypertension [J].

Channick, RN ;

Sitbon, O ;

Barst, RJ ;

Manes, A ;

Rubin, LJ .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :62S-67S

← 1 2 3 4 5 →